NASDAQ:ABVX

Abivax (ABVX) Stock Price, News & Analysis

Abivax logo
$73.52 -7.13 (-8.84%)
Closing price 03:58 PM Eastern
Extended Trading
$74.15 +0.63 (+0.85%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Abivax Stock (NASDAQ:ABVX)

Advanced

Key Stats

Today's Range
$62.70
▼
$79.74
50-Day Range
$80.68
▼
$118.64
52-Week Range
$62.70
▼
$148.83
Volume
14.85 million shs
Average Volume
1.43 million shs
Market Capitalization
$6.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$155.00
Consensus Rating
Moderate Buy

Company Overview

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response.

The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation.

Founded in 2013, Abivax conducts clinical development internationally. Marc de Garidel has served as the company’s chief executive officer.

AI Generated. May Contain Errors.

Abivax Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

ABVX MarketRank™: 
3.54549191559 of 5 stars

Abivax scored higher than 71% of companies evaluated by MarketBeat, and ranked 225th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abivax has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 13 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Abivax has a consensus price target of $155.00, representing about 115.2% upside from its current price of $72.04.

  • Amount of Analyst Coverage

    Abivax has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Abivax's stock forecast and price target.
  • Earnings Growth

    Earnings for Abivax are expected to decrease in the coming year, from ($4.14) to ($4.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abivax is -11.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abivax is -11.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Abivax has a P/B Ratio of 10.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Abivax's valuation and earnings.
  • Percentage of Shares Shorted

    4.70% of the float of Abivax has been sold short.
  • Short Interest Ratio / Days to Cover

    Abivax has a short interest ratio ("days to cover") of 4.63.
  • Change versus previous month

    Short interest in Abivax has recently decreased by 43.34%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Abivax does not currently pay a dividend.

  • Dividend Growth

    Abivax does not have a long track record of dividend growth.

  • News Sentiment

    Abivax has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Abivax this week, compared to 5 articles on an average week.
  • Search Interest

    Only 6 people have searched for ABVX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Abivax to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Abivax insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    47.91% of the stock of Abivax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abivax's insider trading history.
Receive ABVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abivax and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABVX Stock News Headlines

Abivax Statement on Short Seller Report
This is likely to EXPLODE
Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.tc pixel
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Drop in Short Interest
Abivax to Participate in Upcoming Fall Investor Conferences
Abivax SA ADR ABVX
See More Headlines

ABVX Stock Analysis - Frequently Asked Questions

Abivax's stock was trading at $134.85 at the beginning of 2026. Since then, ABVX stock has decreased by 46.6% and is now trading at $72.04.

Abivax SA Sponsored ADR (NASDAQ:ABVX) posted its quarterly earnings data on Monday, September, 21st. The company reported ($1.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by $0.79. The company earned $1.37 million during the quarter, compared to analysts' expectations of $799 thousand.

Abivax (ABVX) raised $230 million in an IPO on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60-$13.00 per share.

Top institutional shareholders of Abivax include RA Capital Management L.P. (1.18%), Logos Global Management LP (0.99%), Aberdeen Group plc (0.87%) and Two Seas Capital LP (0.77%).

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abivax investors own include Broadcom (AVGO), Marvell Technology (MRVL), Micron Technology (MU), Nebius Group (NBIS), NVIDIA (NVDA), Bloom Energy (BE) and MP Materials (MP).

Company Calendar

Last Earnings
9/21/2026
Today
11/20/2026
9th Annual Evercore ISI HealthCONx Conference
12/02/2026
38th Annual Healthcare Conference
12/03/2026
Next Earnings (Estimated)
12/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ABVX
Previous Symbol
NASDAQ:ABVX
CIK
1956827
Fax
N/A
Employees
98
Year Founded
2013

Price Target and Rating

High Price Target
$187.00
Low Price Target
$96.00
Potential Upside/Downside
+110.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$380.27 million
Net Margins
N/A
Pretax Margin
-33,207.73%
Return on Equity
-91.69%
Return on Assets
-71.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.97
Quick Ratio
5.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.57 per share
Price / Book
11.19

Miscellaneous

Outstanding Shares
87,550,000
Free Float
N/A
Market Cap
$6.44 billion
Optionable
Optionable
Beta
1.36

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:ABVX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners